Western Union 2013 Annual Report Download - page 235

2013 FORM 10-K
THE WESTERN UNION COMPANY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
125
(a) Funds included herein have redemption frequencies of daily to monthly, with redemption notice periods of one to ten business
days.
(b) Substantially all corporate debt securities are investment grade securities.
(c) Hedge funds generally hold liquid and readily priceable securities, such as public equities, exchange-traded derivatives, and
corporate bonds. Hedge funds themselves do not have readily available market quotations, and therefore are valued using
the Net Asset Value ("NAV") per share provided by the investment sponsor or third party administrator. Funds investing in
diverse hedge fund strategies (primarily commingled funds) had the following composition of underlying hedge fund
investments within the pension plan at December 31, 2013: relative value (24%), equity long/short (21%), commodities/
currencies (20%), multi-strategy (13%), event driven (12%), and global-macro (10%). As of December 31, 2013, funds
included herein had redemption frequencies of monthly to quarterly, with redemption notice periods of three to 60 days.
(d) Diversified investments in royalty rights related to the sale of pharmaceutical products by third parties. Also included are
private equity funds with a focus on venture capital. These investments are illiquid, with investment distributions expected
to be received over the lives of the funds, which are uncertain but based on the voting rights of investors and the maturities
of the underlying investments.
The maturities of debt securities as of December 31, 2013 range from less than one year to approximately 32 years with a
weighted-average maturity of 14 years.
The following tables provide summaries of changes in the fair value of the Trust's Level 3 financial assets (in millions):
Royalty
Rights
Private
Equity Total
Balance, January 1, 2012. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 11.4 $ 2.2 $ 13.6
Actual return on plan assets:
Relating to assets still held as of the reporting date . . . . . . . . . . . . . . . . . . . . . . . . 1.6 0.1 1.7
Relating to assets sold during the year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.8 (0.1) 0.7
Net purchases and sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.6 0.2 7.8
Balance, December 31, 2012. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 21.4 $ 2.4 $ 23.8
Actual return on plan assets:
Relating to assets still held as of the reporting date . . . . . . . . . . . . . . . . . . . . . . . . 2.3 0.3 2.6
Relating to assets sold during the year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.6 0.1 1.7
Net purchases and sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (2.0)(0.2)(2.2)
Balance, December 31, 2013. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 23.3 $ 2.6 $ 25.9
Royalty rights are held through investment funds. These investments are priority interests in contractual royalty revenue
derived from the sale of pharmaceutical products that entitle the investment fund to receive a portion of revenue from the patent-
protected product. The fair value of the Company's investment in royalty rights is estimated using consensus sales estimates for
the pharmaceutical products obtained from third-party experts, which are multiplied by the contractual royalty rate, and then
discounted by an interest rate based off the estimated weighted average cost of capital of the pharmaceutical sector (approximately
10%).
Private equity funds invest in the non-marketable securities of individual private companies. These private companies
ultimately may become public in the future. The fair value of the Company's investment in private equity funds is estimated using
many types of inputs, including historical sales multiples, valuations of comparable public companies, and recently completed
equity financings.